Browse by Audience
MEMBER

Update Your Profile
Special Interest Groups (SIG)
Member Spotlights
IASP Connect
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Pain Researcher
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Curricula
Graduate Opportunities
Treatment and Education Resources
Events

PATIENT & CAREGIVER

Resources for Living with Pain
Topic Pages
Free Videos
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner
Make a Donation

I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease: An Evidence-Based Analysis.

< BACK TO ARCHIVE


2022


Front Med (Lausanne)


http://www.ncbi.nlm.nih.gov/pubmed/35252236?dopt=Abstract


9

Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie’s Disease: An Evidence-Based Analysis.

Authors

Efficacy and Safety of Collagenase Clostridium Histolyticum in the Treatment of Peyronie's Disease: An Evidence-Based Analysis.
Cao D, Li J, Lu Y, Huang Y, Chen B, Chen Z, Shen Y, Liu L, Wei Q
Front Med (Lausanne). 2022; 9:780956.
PMID: 35252236.

Abstract

Peyronie's disease (PD) is a chronic wound healing disorder, mainly involving tunica albuginea. Collagenase Clostridium Histolyticum (CCH) has shown its effectiveness in treating PD, but its efficacy and safety remain controversial, which propelled us to conduct the first evidence-based research on this topic.
Read This Paper